Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.43 |
| ▸ | CCR4 | P51679 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178000 | 0.99 | MCHR1 (0.42) | MCHR1CCR4BACE1KCNH2KDM4E | |
| SCHEMBL2177400 | 0.94 | CCR4 (0.40) | MCHR1CCR4 | |
| SCHEMBL2175171 | 0.89 | CCR4 (0.39) | MCHR1CCR4DRD3 | |
| SCHEMBL2178011 | 0.88 | CCR4 (0.38) | MCHR1CCR4DRD3 | |
| SCHEMBL2176019 | 0.86 | CCR4 (0.38) | MCHR1CCR4KCNH2 | |
| SCHEMBL2174669 | 0.86 | CCR4 (0.37) | MCHR1CCR4DRD3 | |
| SCHEMBL2174961 | 0.86 | CCR4 (0.38) | MCHR1CCR4 | |
| SCHEMBL2174575 | 0.85 | MTNR1A (0.38) | CCR4 | |
| SCHEMBL2175778 | 0.85 | CYP2D6 (0.38) | MCHR1CCR4 | |
| SCHEMBL2178111 | 0.84 | CCR4 (0.41) | MCHR1CCR4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948601-B1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | CRYSTALGENOMICS INC (KR) | 2016-04-13 | — | — | EP | claimed |
| US-7973060-B2 | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS, INC. (KR) | 2011-07-05 | — | — | US | claimed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | claimed |
| EP-1948601-B1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | CRYSTALGENOMICS INC (KR) | 2016-04-13 | — | — | EP | disclosed |
| US-7973060-B2 | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS, INC. (KR) | 2011-07-05 | — | — | US | disclosed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | TFPI, TFPI2, FCGRT | MCHR1 4586/4885CCR4 4278/4885BACE1 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.